BioAge Labs (BIOA) Fundamental Analysis: Revenue, Earnings & Valuation

1.22 / 10

Underperform

Fundamental rating is Underperform with a 1.2/10 score. Strengths include accounts receivable turnover and interest coverage, while income‑tax ratio and PB‑ROE are weak. Overall, the financial profile is poor, indicating selective positioning.

Analysis Checks(6/10)

Revenue-MV

Value-2.92

Score1/3

Weight30.74%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight3.08%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-3.29%

1M Return-0.67%

Accounts receivable turnover ratio

Value22.98

Score2/3

Weight-3.26%

1M Return-0.65%

PB-ROE

Value-0.37

Score1/3

Weight30.75%

1M Return5.22%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-7.41%

1M Return-1.54%

Fixed assets turnover ratio

Value2.55

Score3/3

Weight4.34%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-3.68%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-3.61%

1M Return-0.74%

Asset-MV

Value-0.48

Score1/3

Weight52.35%

1M Return7.28%

Is BIOA undervalued or overvalued?

BIOA scores 1.22/10 on fundamentals and holds a Premium valuation at present. Backed by its -27.09% ROE, 0.00% net margin, -9.04 P/E ratio, 2.68 P/B ratio, and 66.21% earnings growth, these metrics solidify its Underperform investment rating.